secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-07-27T12:30:31+00:00
Accession:  0001493152-26-034711
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies publishes clinical framework for CyPath Lung in nodule evaluation
--------------------------------------------------------------------------------

- White paper by CMO Gordon Downie proposes specialty-specific pathways for pulmonology, primary care, oncology using CyPath Lung.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with small nodules.
- Company reports 7.78M shares outstanding, market cap ~$5.1M as of July 24, 2026.
- CyPath Lung analyzes sputum for lung microenvironment, not blood-based, providing real-time information.
- Complete white paper available at https://bit.ly/cypath-lung-whitepaper3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226034711/0001493152-26-034711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226034711/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer